Abstracts tagged "Lupus"

Abstract Number: 653 • 2014 ACR/ARHP Annual Meeting
Dermal Injury Promotes Nephritis Flare in Lupus-Prone NZM2328 Mice
Kaitlyn Clark¹, Tamra J. Reed¹, Jeffrey B. Hodgin² and J. Michelle Kahlenberg³, ¹Internal Medicine, Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Pathology, University of Michigan, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic lupus erythematosus is an autoimmune disease with pleotropic manifestations, including severe skin disease, hematologic abnormalities and nephritis. Clinically, lupus is characterized by episodes…
Abstract Number: 1922 • 2014 ACR/ARHP Annual Meeting
Hydroxylchloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples
Rufei Lu^1,2, Adam Przebinda³, Melissa E. Munroe⁴, Joel M. Guthridge¹, Joan T. Merrill⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder with a waxing and waning clinical course. Hydroxychloroquine (HCQ) is a well-tolerated and effective…
Abstract Number: 858 • 2014 ACR/ARHP Annual Meeting
ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets
Li Chun Wang¹, Stuart Perper¹, Annette Schwartz², Christian Goess³, Liz O'connor⁴, Dawna Hartman², Candace Graff², Andrew Souers⁵, Joel Leverson⁵, Steven Elmore⁵ and Lisa Olson², ¹Immunology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ³Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁴Toxicology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, ⁵AbbVie Inc, North Chicago, IL
Background/Purpose Proteins in the BCL-2 family are key regulators of apoptosis, or programmed cell death. Navitoclax, a selective inhibitor of both BCL-2 and BCL-X(L) demonstrated…
Abstract Number: 652 • 2014 ACR/ARHP Annual Meeting
Identification of Eat-2 As a Lupus Susceptibility Gene in New Zealand Black (NZB) Mice That Regulates Dendritic Cell Function
Nafiseh Talaei¹ and Joan E. Wither², ¹Genetics and Development, Toronto Western Research Institute, Toronto, ON, Canada, ²1E420/Div of Rheumatology, Toronto Western Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: We have previously shown that B6 mice with an introgressed homozygous NZB chromosome (c) 1 interval (70 to 100 cM) develop high titres of…
Abstract Number: 1876 • 2014 ACR/ARHP Annual Meeting
Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses’ Health Studies
Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks, Elizabeth W. Karlson and Karen H. Costenbader, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Prior case-control studies have reported an inverse association between moderate alcohol consumption and the development of SLE. However, case-control studies may be prone to…
Abstract Number: 856 • 2014 ACR/ARHP Annual Meeting
A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus
Silvio M. Vieira¹, Andrew Yu¹, Michael Hiltesperger¹, Odelya E. Pagovich¹, Eleni Tiniakou¹, William Ruff², John Sterpka¹ and Martin Kriegel^2,3, ¹Yale School of Medicine, New Haven, CT, ²Immunobiology, Yale School of Medicine, New Haven, CT, ³Medicine, Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: The etiology of lupus-associated antiphospholipid syndrome (APS) is unknown but microbial triggers have been implicated in transient antiphospholipid antibody production in both mice and…
Abstract Number: 645 • 2014 ACR/ARHP Annual Meeting
The Combination of Metformin and 2-Deoxy-D-Glucose Normalizes CD4 T Cell Metabolism and Functions, and Reverse Disease in Murine Models of Lupus
Laurence Morel¹, Yiming Yin², Seung-Chul Choi², Eric S. Sobel³ and Byron Croker², ¹Pathology/Immunology/Lab Medical, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL
Background/Purpose: Autoreactive CD4 T cells are key effectors in Systemic Lupus Erythematosus (SLE). Cell metabolism is an important checkpoint for T cell activationand differentiation. Both…
Abstract Number: 1827 • 2014 ACR/ARHP Annual Meeting
Anti-Ro and Anti-La Antibodies in the General Pregnant Population
Evelyn V. Rozenblyum¹, Sharon Sukhdeo², Edgar Jaeggi³, Lisa Hornberger⁴, Philip Wyatt⁵, Carl A. Laskin⁶ and Earl D. Silverman⁷, ¹Pediatrics, University of Toronto, Toronto, ON, Canada, ²Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ³Cardiology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴Pediatric Cardiology , Tel: 780-407-3355; Fax: 780-407-3954;, Stollery Children's Hospital, Edmonton, ON, Canada, ⁵Department of Genetics, North York General Hospital, Toronto, ON, Canada, ⁶University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose Neonatal lupus erythematosus (NLE) is a passively transferred autoimmune disease that occurs in babies born to pregnant women with anti-Ro and anti-La antibodies. The…
Abstract Number: 704 • 2014 ACR/ARHP Annual Meeting
Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort
Ruba Kado¹, Emily Siegwald², Emily Lewis², Mitch Goodsitt³, Emmanuel Christodoulou³, Ella Kazerooni³ and W. Joseph McCune⁴, ¹Internal Medicine-Rheumatology, University of Michigan, Ann Arbor, MI, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Ionizing radiation from CT scanning can increase cancer risk. Lupus patients are frequently evaluated for chest pain and may have multiple pulmonary embolism CT…
Abstract Number: 644 • 2014 ACR/ARHP Annual Meeting
HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis and Extends Life Spans in Lupus Prone MRL/Lpr Mice
Yu Cai¹, Zhipeng Wu¹, Ping Ren¹, Xiaoming Dai¹, Jianlin He¹, Fang Yin¹, Wei Deng¹, Guangxiu Dai¹, Weiguo Su¹ and Xiong Li², ¹Hutchison Medipharma Limited, Shanghai, China, ²Building 4, 720 Cai Lun Road,, Hutchison Medipharma Limited, Shanghai, China
Background/Purpose: Syk is a key mediator of signaling events downstream of a wide array of receptors important for immune functions, including the B cell receptor,…
Abstract Number: 1807 • 2014 ACR/ARHP Annual Meeting
Problems with Fee for Service Payments for Academic Rheumatology Practices: A Need for Payment Reform:
Allen P. Anandarajah¹ and Christopher T. Ritchlin², ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The current fee-for-service model rewards providers for the volume of services. The model is designed to deliver higher compensation for care of more complex cases. Rheumatologists…
Abstract Number: 719 • 2014 ACR/ARHP Annual Meeting
Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials
Chris Morehouse¹, Linda Chang², Liangwei Wang³, Philip Brohawn¹, Shinya Ueda⁴, Gabor Illei⁵, Warren Greth³, Stephen Yoo⁶, Lorin Roskos⁷, Yihong Yao⁸, Gabriel Robbie⁹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Sciences, MedImmune, Hayward, CA, ³MedImmune, LLC, Gaithersburg, MD, ⁴PK, Astrazeneca, Osaka, Japan, ⁵Clinical Development, Medimmune, Gaithersburg, MD, ⁶Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁷One MedImmune Way, Medimmune, Gaithersburg, MD, ⁸Translational Sciences, MedImmune, Gaithersburg, MD, ⁹Clinical Pharmacology and DMPK, MedImmune, Gaithersburg, MD
Background/Purpose The pharmacokinetic (PK) and pharmacodynamic (PD) effects of two investigational monoclonal antibodies inhibiting type I IFN signaling - sifalimumab or anifrolumab, specific for IFN-α…
Abstract Number: 642 • 2014 ACR/ARHP Annual Meeting
Treatment with a Glycolipid Ameliorates Lupus Dermatitis and Expands Skin ãä T Cells That Promote the Migration of Langerhans Dendritic Cells
Ram Raj Singh^1,2,3, Anna Eriksson¹, Darshan Randhawa¹ and Miguel-Angel Gutierrez¹, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, ³Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA
Background/Purpose: Self antigens are taken from tissues to local lymphoid organs to acquire ability to avoid self-reactivity. This important immune function is accomplished by dendritic…
Abstract Number: 2870 • 2014 ACR/ARHP Annual Meeting
B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus
Shaun W. Jackson^1,2, Nicole Scharping¹, Socheath Khim¹ and David Rawlings^1,2, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics, University of Washington, Seattle, WA
Background/Purpose Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and patients with SLE frequently express a “type 1 IFN gene signature”. Type 1…
Abstract Number: 1646 • 2014 ACR/ARHP Annual Meeting
Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-IFNγ)
Barbara Sullivan¹, Roberto Guzman², Christopher B. Russell³, Greg Arnold⁴, Michael Boedigheimer¹, Connie Ma⁵, James Chung¹, Victoria P. Werth^6,7 and David A. Martin³, ¹Amgen, Thousand Oaks, CA, ²Pathology, Amgen, Thousand Oaks, CA, ³Medical Sciences, Amgen, Seattle, WA, ⁴Medical Sciences, Amgen, Thousand Oaks, CA, ⁵Clinical Immunology, Amgen, Thousand Oaks, CA, ⁶Department of Dermatology, Veteran Affairs Medical Center, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose Discoid Lupus Erythematosus (DLE), the most common chronic cutaneous form seen in LE, includes inflammation leading to scarring, telangiectasias, atrophy, and/or dyspigmentation. Elevated levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].